Saladax Secures $9M Loan Facility from GE Capital | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax Biomedical today announced the completion of a $9 million debt financing with GE Capital.

The secured loan facility will be used to support commercialization of Saladax's My5-FU assay, which measures levels of 5-flourouracil, a chemotherapy used in conjunction with other therapies for colorectal cancer and other solid tumors. The test is currently available in the European Union and Australia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.